Recommendations For Estimating Utility Values From Other Health Measures

Published Jan 17, 2013
Sheffield, UK - Decision-making agencies, such as the National Institute for Health and Clinical Excellence (NICE) in the UK, recommend the inclusion of utility data in health technology assessments, and sometimes require data to be collected using specific patient-reported outcome measures such as the EQ-5D. This creates a problem if those specific measures have not been included within the clinical research programme. 'Mapping' is an analytical technique that can be used to predict EQ-5D or other utility data when they have not been collected directly as part of the planned clinical research programme and can facilitate the calculation of quality adjusted life years. It does this by estimating an empirical relationship between the utility measure and other clinical or quality of life data from a secondary source. In the paper, “Mapping to obtain EQ-5D utility values for use in NICE health technology assessments,” published in Value in Health, Dr. Louise Longworth, (PhD, MSc, BA Hons), Reader in Health Economics at Brunel University, UK, and Dr. Donna Rowen from the University of Sheffield, UK, present an overview of how to conduct 'mapping' in order to estimate health-related utility. They provide details on how mapping has been used by other researchers based on a review of the published literature, and how it has been used by the health-care decision-making body, NICE, in the UK. They outline best current practice and highlight where further research is required. Dr. Longworth states, "Mapping is a useful method for capturing utility data within health technology assessments (HTA), but the standards of analysis and reporting have too often been poor when presented to decision-makers in submissions. We hope that this paper will offer practical advice to analysts wishing to conduct and present their own mapping analyses in HTA submissions"

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×